CORONA, Calif., Sept. 13 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, today announced that the company has completed its $300 million share repurchase program. The share repurchase program was announced in February 2005 and authorized the repurchase of up to $300 million of the company's common stock over a one year period. Watson has repurchased a total of approximately 9.4 million shares, or $300 million of its common stock, under the share repurchase program.
About Watson Pharmaceuticals, Inc.
Watson Pharmaceuticals, Inc., headquartered in Corona, California, is a leading specialty pharmaceutical company that develops, manufactures, markets, sells and distributes brand and generic pharmaceutical products. Watson pursues a growth strategy combining internal product development, strategic alliances and collaborations and synergistic acquisitions of products and businesses.
For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watsonpharm.com .
(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO )
Photo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGOWatson Pharmaceuticals, Inc.CONTACT: Patty Eisenhaur, Director, Investor Relations, +1-951-493-5611,Watson Pharmaceuticals, Inc.
Web site: http://www.watsonpharm.com/
